Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Sexual functioning and depressive symptoms in men with various types of prediabetes: a pilot study

International Journal of Impotence Research volume 30, pages 327–334 (2018)Cite this article

Subjects

Abstract

No study has compared sexual functioning and depressive symptoms in male subjects with various types of prediabetes. Our study included four age- and weight-matched groups of apparently healthy men (25–50 years old): subjects with isolated impaired fasting glucose (IFG) (n = 16), men with isolated impaired glucose tolerance (n = 17), individuals with the presence of both IFG and impaired glucose tolerance (n = 16), as well as men with normal glucose tolerance (n = 18). All included men completed questionnaires evaluating male sexual functioning (IIEF-15) and assessing the presence and severity of depressive symptoms (BDI-II). Men with both IFG and impaired glucose tolerance obtained lower domain scores for erectile function, sexual desire, and overall satisfaction, as well as the higher overall BDI-II score. Individuals with isolated impaired glucose tolerance (IGT) and IFG were characterized by lower domain score only for sexual desire. In all study groups, domain score for erectile function correlated with the BDI-II score, while scores for erectile function and sexual desire correlated with a degree of insulin resistance. The obtained results suggest that prediabetes may impair sexual functioning in young men. The risk is particularly high in individuals with the presence of both IFG and IGT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.

    Article  CAS  Google Scholar 

  2. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology. 2004;64:1196–201.

    Article  Google Scholar 

  3. Moreira ED Jr., Lbo CF, Diament A, Nicolosi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 2003;61:431–6.

    Article  Google Scholar 

  4. Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, et al. Erectile dysfunction in type1 and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol. 2000;29:524–31.

    Article  CAS  Google Scholar 

  5. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care. 2002;25:1458–63.

    Article  Google Scholar 

  6. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, et al. Clinical and psychological predictors of incidence of self-reported erectile dysfunction in patients with type 2 diabetes. J Urol. 2007;177:252–7.

    Article  Google Scholar 

  7. Rabijewski M, Papierska L, Kuczerowski R, Piątkiewicz P. Hormonal determinants of erectile dysfunction and lower urinary tract symptoms in middle-aged and elderly men with prediabetes. Aging Male. 2015;18:256–64.

    Article  CAS  Google Scholar 

  8. Corona G, Rastrelli G, Balercia G, Lotti F, Sforza A, Monami M, et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med. 2012;9:1669–80.

    Article  CAS  Google Scholar 

  9. Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166:213–9.

    Article  Google Scholar 

  10. Maseroli E, Corona G, Rastrelli G, Lotti F, Cipriani S, Forti G, et al. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med. 2015;12:956–65.

    Article  Google Scholar 

  11. Ettala OO, Korhonen PE, Syvänen KT, Kaipia AJ, Vahlberg TJ, Aarnio PT, et al. Erectile dysfunction cannot be used in primary screening of prediabetes. Diabetes Res Clin Pract. 2015;108:e60–e62.

    Article  Google Scholar 

  12. Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopień B. Sexual functioning and depressive symptoms in women with diabetes and prediabetes receiving metformin therapy: a pilot study. Exp Clin Endocrinol Diabetes. 2017;125:42–48.

    CAS  PubMed  Google Scholar 

  13. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR, Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186:461–5.

    PubMed  Google Scholar 

  14. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res. 2005;2:9–15.

    Article  Google Scholar 

  15. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29:1130–9.

    Article  CAS  Google Scholar 

  16. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance andimpaired fasting glucose. Am J Cardiol. 2011;108(Suppl. 3):3B–24B.

    Article  CAS  Google Scholar 

  17. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701–10.

    Article  CAS  Google Scholar 

  18. Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care. 1999;22:1490–3.

    Article  CAS  Google Scholar 

  19. Krysiak R, Szkróbka W, Okopień B. The effect of l-thyroxine treatment on sexual function and depressive symptoms in men with autoimmune hypothyroidism. Pharmacol Rep. 2017;69:432–7.

    Article  CAS  Google Scholar 

  20. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226–44.

    Article  CAS  Google Scholar 

  21. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999;54:346–51.

    Article  CAS  Google Scholar 

  22. Beck AT, Steer RA, Brown GK BDI-II: Beck Depression Inventory Manual. Edn 2. Psychological Corporation, San Antonio, 1996.

  23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders—DSM-IV-TR. Edn 4. Washington: American Psychiatric Publishing; 1994.

    Google Scholar 

  24. Zawadzki B, Popiel A, Praglowska E, Psychometric properties of the polish version of the Aaron T. Beck’s depression inventory BDI-II. Psychol Etol Genet. 2009;19:71–95.

    Google Scholar 

  25. Corona G, Isidori AM, Aversa A, Burnett AL, Maggi M. Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med. 2016;13:317–37.

    Article  Google Scholar 

  26. Cunningham GR. Testosterone and metabolic syndrome. Asian J Androl. 2015;17:192–6.

    Article  CAS  Google Scholar 

  27. Arthur R, Rohrmann S, Møller H, Selvin E, Dobs AS, Kanarek N, et al. Pre-diabetes and serum sex steroid hormones among US men. Andrology. 2017;5:49–57.

    Article  CAS  Google Scholar 

  28. Kher N, Marsh JD. Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost. 2004;30:665–72.

    Article  CAS  Google Scholar 

  29. Krysiak R, Okopień B. The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. Atherosclerosis. 2010;213:325–8.

    Article  CAS  Google Scholar 

  30. Krysiak R, Gdula-Dymek A, Bachowski R, Okopień B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of prediabetes. Diabetes Care. 2010;34:2266–70.

    Article  Google Scholar 

  31. Dimova R, Tankova T, Guergueltcheva V, Tournev I, Chakarova N, Grozeva G, et al. Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance. J Diabetes Complicat. 2017;31:537–43.

    Article  Google Scholar 

  32. Cortez M, Singleton JR, Smith AG. Glucose intolerance, metabolic syndrome, and neuropathy. Handb Clin Neurol. 2014;126:109–22.

    Article  Google Scholar 

  33. Pedro-Botet J, Flores-Le Roux JA, Mostaza JM, Pintó X, de la Cruz JJ, Banegas JR. Atherogenic dyslipidemia: prevalence and management in lipid clinics. Rev Clin Esp. 2014;214:491–8.

    Article  CAS  Google Scholar 

  34. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  Google Scholar 

  35. Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, et al. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017;60:1601–11.

    Article  CAS  Google Scholar 

  36. Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopień B Sexual functioning and depressive symptoms in women with various types of prediabetes: a pilot study. Endokrynol Pol 2018;69:175–81. [in press].

  37. Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci. 2013;14:135–51.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

    Robert Krysiak, Witold Szkróbka & Bogusław Okopień

Authors
  1. Robert Krysiak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Witold Szkróbka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bogusław Okopień
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Krysiak.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krysiak, R., Szkróbka, W. & Okopień, B. Sexual functioning and depressive symptoms in men with various types of prediabetes: a pilot study. Int J Impot Res 30, 327–334 (2018). https://doi.org/10.1038/s41443-018-0050-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41443-018-0050-6

Search

Advanced search

Quick links